Meridian Bioscience (NASDAQ: VIVO) announced that it has received the CE Mark for two new molecular diagnostic tests for Chlamydia ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE